Goldman Sachs about gene therapy: 'Is curing patients a sustainable business model?'
Tags:
Goldman Sachs analysts attempted to address a touchy subject for biotech companies, especially those involved in the pioneering "gene therapy" treatment: cures could be bad for business in the long run
About This Document
File info